烟酰胺磷酸核糖转移酶
化学
癌症研究
酶
代谢稳定性
结合
药品
NAD+激酶
作用机理
行动方式
生物化学
药物输送
代谢途径
药理学
烟酰胺
新陈代谢
生物相容性材料
肿瘤细胞
细胞培养
癌症
作者
Pablo Ruedas,Hendrik Gruß,Alexander Hempelmann,Marija Vranic,Sarah‐Jane Neuberth,Valentin Petrich,Dominic Gross,Anikó Pálfí,Andreas M Pahl,Torsten Hechler
标识
DOI:10.1021/acsbiomedchemau.6c00047
摘要
Antibody drug conjugates (ADCs) enable selective delivery of highly potent small molecules, yet most clinically validated payloads target solely cell-division pathways with several drawbacks such as high off-target toxicity and a lack of efficacy on nondividing tumor cells (e.g., tumor stem cells). Metabolic targets such as nicotinamide phosphoribosyltransferase (NAMPT) offer a complementary mode of action and are predestined as ADC payloads since systemic toxicities have prevented clinical use of NAMPT inhibitors (NAMPTi) as free drugs. Here we show that highly hydrophobic NAMPTi, especially cyanoguanidine-containing inhibitors, are chemically and metabolically suboptimal for ADC deployment due to limited efficacy likely due to lysosomal conversion to inactive guanylureas. Guided by structure-based design, and molecular dynamics simulations, we developed two next-generation NAMPT inhibitors featuring (i) a tertiary alcohol to balance hydrophilicity and (ii) an isoindoline-urea group to improve lysosomal stability in comparison to the cyanoguanidine. The optimized inhibitors retained high affinity to the NAMPT enzyme and showed strong cellular activity upon targeted delivery through ADCs. When conjugated to anti-CD30, anti-HER2, or anti-TROP2 antibodies, the resulting ADCs showed durable responses in hematologic and solid tumor models, including complete regressions in the metabolically stringent NCI-N87 gastric carcinoma xenograft after a single 2 mg/kg dose. These findings highlight physicochemical tuning and lysosomal stability as key design principles for NAMPT-based payloads and support NAMPT inhibition as a very promising mode of action (MoA) for next-generation ADC therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI